(4-氨基-2-氯苯基)(苯基)甲酮 | 61747-12-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: (4-氨基-2-氯苯基)(苯基)甲酮
• 英文名称: (4-Amino-2-chlorphenyl)phenylketon
• 英文别名: (4-amino-2-chlorophenyl)(phenyl)methanone；4-Amino-2-chlorbenzophenon；4-amino-2-chlorobenzophenone；(4-amino-2-chlorophenyl)-phenylmethanone
• CAS: 61747-12-4
• 化学式: C₁₃H₁₀ClNO
• 分子量: 231.681
• InChiKey: LPWVIVSQYVJOLX-UHFFFAOYSA-N

物化性质

• 熔点：
  143.5-144.5 °C
• 沸点：
  410.6±30.0 °C(Predicted)
• 密度：
  1.274±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  43.1
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2922399090

反应信息

• 作为反应物：
  描述：

  (4-氨基-2-氯苯基)(苯基)甲酮 在 sodium nitrite 作用下， 以66%的产率得到(2-氯-4-羟基苯基)苯基酮
  参考文献：
  名称：

  Effenberger, Franz; Gutmann, Rainer, Chemische Berichte, 1982, vol. 115, # 3, p. 1089 - 1102

  摘要：

  DOI：
• 作为产物：
  描述：

  2-氯-4-硝基苯甲酰氯 在 正丁基锂 、 tin(ll) chloride 作用下， 以 四氢呋喃 、 乙醇 、 正己烷 为溶剂， 反应 6.33h， 生成 (4-氨基-2-氯苯基)(苯基)甲酮
  参考文献：
  名称：

  Synthesis and Structure−Activity Relationship of Aminobenzophenones. A Novel Class of p38 MAP Kinase Inhibitors with High Antiinflammatory Activity

  摘要：

  We wish to report the synthesis and structure-activity relationship (SAR) of a series of 4-aminobenzophenones, as a novel compound class with high antiinflammatory activity. Our initial lead, {4-[(2-aminophenyl)amino]phenyl}(phenyl)methanone (3), was systematically optimized and resulted in compounds that potently inhibited the release of the proinflammatory cytokines IL-1beta and TNF-alpha in human peripheral blood mononuclear cells stimulated by LPS. One of the most potent compounds, among others, was {4-[(2-aminophenyl)amino]-2-chlorophenyl}(2-methylphenyl)methanone (45) with IC50 values of 14 and 6 nM for the inhibition of IL-1beta and TNF-alpha, respectively. Furthermore, we found these types of compounds to be potent and selective p38 MAP kinase inhibitors, e.g. 45 had an IC50 value of 10 nM. Molecular modeling was used to rationalize our SAR data and to propose a model for the interaction of compound 45 with the p38 MAP kinase. The model involved a favorable hydrogen bond between the carbonyl group of the benzophenone and the NH of Met-109, positioning ring A in the hydrophobic pocket I of the enzyme. Good antiinflammatory effects were demonstrated in two murine models of dermatitis after topical application (oxazolone and TPA model).

  DOI：

  10.1021/jm030851s

文献信息

• Aniline derivatives
  申请人：Zeneca Limited

  公开号：US05821246A1

  公开（公告）日：1998-10-13

  The invention concerns aniline derivatives of formula I ##STR1## wherein m is 1, 2 or 3, n is 0, 1, 2 or 3, Q is phenyl or naphthyl or a 5- or 6-membered heteroaryl moiety containing 1, 2 or 3 heteroatoms selected from oxygen, nitrogen and sulfur, and X, R.sup.1 and R.sup.2 are defined in the claims; or pharmaceutical compositions containing them, and the methods of using the compounds as tyrosine kinase inhibitors and for the treatment of proliferative diseases such as cancer.

  本发明涉及公式I的苯胺衍生物：##STR1##，其中m为1、2或3，n为0、1、2或3，Q为苯基或萘基或含氧、氮、硫的1、2或3个杂原子的5或6元杂芳基基团，X、R1和R2的定义见权利要求；或包含它们的药物组合物，以及使用该化合物作为酪氨酸激酶抑制剂和治疗诸如癌症的增殖性疾病的方法。
• Trisubstituted carbocyclic cyclophilin binding compounds and their use
  申请人：——

  公开号：US20020165275A1

  公开（公告）日：2002-11-07

  The present invention relates to novel, non-peptidic small organic compounds having an affinity for cyclophilin (CyP)-type immunophilin proteins, and to pharmaceutical compositions comprising one or more of the said compounds. The invention further relates to the uses of these compounds and compositions for binding CyP-type proteins, inhibiting their peptidyl-prolyl isomerase activity, and for research, development, and therapeutic applications in a variety of medical disorders.

  本发明涉及一种新型的非肽类小有机化合物，其具有与环肽亚精蛋白（CyP）型免疫蛋白亲和力，并且涉及包含所述化合物中的一个或多个的药物组合物。该发明还涉及这些化合物和组合物用于结合CyP型蛋白，抑制其肽基脯氨酸异构酶活性，并在各种医学疾病的研究、开发和治疗应用中的用途。
• Coumarin-surfactant modified polyoxometalate catalyzed cross dehydrogenative coupling of benzyl alcohol with the <i>para</i>-C–H of unprotected aniline
  作者：Qian Xu、Gang Yu、Min Liu、Chang Peng、M. Katherine Banks、Weijian Xu、Ruoxi Wu、Yanbing Lu

  DOI：10.1039/c8cy01423j

  日期：——

  novel method for synthesizing para-aminobenzophenone and its derivatives (p-ABPs) using a coumarin-surfactant modified polyoxometalate as the catalyst. Preliminary mechanistic studies indicate that the reaction has undergone an oxidative cross dehydrogenative coupling process. This method has the advantages of an easy process, a convenient raw material source, safe and green oxidants, and tolerances

  本文提出了一种以香豆素表面活性剂改性的多金属氧酸盐为催化剂合成对氨基二苯甲酮及其衍生物（p -ABPs）的新方法。初步的机理研究表明该反应经历了氧化交叉脱氢偶联过程。这种方法的优点是易于加工，方便的原料来源，安全和绿色的氧化剂以及对几个官能团的耐受性。
• 4-anilinoquinazoline derivatives bearing a heteroaryl substituted at the
  申请人：Zeneca Limited

  公开号：US05955464A1

  公开（公告）日：1999-09-21

  The invention concerns 4-anilinoquinazoline derivatives of the formula I ##STR1## wherein m is 1 or 2; each R.sup.1 includes hydrogen, halogeno, (1-4C)alkyl and (1-4C)alkoxy; n is 1, 2 or 3; each R.sup.2 includes hydrogen, hydroxy, halogeno and (1-4C)alkyl; and Ar is a 5- or 9-membered nitrogen-linked heteroaryl moiety containing up to four nitrogen heteroatoms, or Ar is a 5-, 6-, 9- or 10-membered nitrogen-linked unsaturated heterocyclic moiety containing up to three nitrogen heteroatoms which bears one or two substituents selected from oxo and thioxo such as 2-oxo-4-imidazolin-1-yl; or a pharmaceutically-acceptable salt thereof; processes for their preparation, pharmaceutical compositions containing them, and the use of the receptor tyrosine kinase inhibitory properties of the compounds in the treatment of proliferative disease such as cancer.

  这项发明涉及式I的4-苯胺基喹唑啉衍生物 其中m为1或2；每个R.sup.1包括氢、卤代、(1-4C)烷基和(1-4C)烷氧基；n为1、2或3；每个R.sup.2包括氢、羟基、卤代和(1-4C)烷基；Ar为含有最多四个氮杂原子的5-或9-成员氮链杂芳基团，或Ar为含有最多三个氮杂原子的5-、6-、9-或10-成员氮链不饱和杂环基团，其带有一个或两个从氧代和硫代氧代中选择的取代基，如2-氧代-4-咪唑啉-1-基；或其药学上可接受的盐；它们的制备方法，含有它们的药物组合物，以及在治疗增生性疾病如癌症中利用这些化合物的受体酪氨酸激酶抑制性能。
• Model studies on a synthetically facile series of N-substituted phenyl-N′-pyridin-3-yl ureas leading to 1-(3-pyridylcarbamoyl) indolines that are potent and selective 5-HT2C/2B receptor antagonists
  作者：Steven M. Bromidge、Steven Dabbs、David T. Davies、Susannah Davies、D.Malcolm Duckworth、Ian T. Forbes、Angela Gadre、Peter Ham、Graham E. Jones、Frank D. King、Damian V. Saunders、Kevin M. Thewlis、Deepa Vyas、Thomas P. Blackburn、Vicky Holland、Guy A. Kennett、Graham J. Riley、Martyn D. Wood

  DOI：10.1016/s0968-0896(99)00228-x

  日期：1999.12

  antagonists have been prepared by rapid parallel synthesis. These N-substituted phenyl-N'-pyridin-3-yl ureas were found to have a range of 5-HT2C receptor affinities and selectivities over the closely related 5-HT2A receptor. Extrapolation of simple SAR, derived from this set of compounds, to the more active but synthetically more complex 1-(3-pyridylcarbamoyl)indoline series allowed us to target optimal

  已经通过快速平行合成制备了一系列的5-HT 2C拮抗剂模型。发现这些N-取代的苯基-N'-吡啶-3-基脲比密切相关的5-HT2A受体具有一系列的5-HT2C受体亲和力和选择性。从这组化合物中衍生出的简单SAR外推至活性更高但合成上更复杂的1-（3-吡啶基氨基甲酰基）二氢吲哚系列，使我们能够靶向最佳取代模式并鉴定有效和选择性的5-HT（2C / 2B）拮抗剂。